YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

Julien Fitamant, Filippos Kottakis, Samira Benhamouche, Helen S. Tian, Nicolas Chuvin, Christine A. Parachoniak, Julia M. Nagle, Rushika M. Perera, Marjorie Lapouge, Vikram Deshpande, Andrew X. Zhu, Albert Lai, Bosun Min, Yujin Hoshida, Joseph Avruch, Daniela Sia, Genís Campreciós, Andrea I. McClatchey, Josep M. Llovet, David MorrisseyLakshmi Raj, Nabeel Bardeesy

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of YAP-mediated hepatocyte reprogramming and HCC pathogenesis. YAP functions as a rheostat in maintaining metabolic specialization, differentiation, and quiescence within the hepatocyte compartment. Increased or decreased YAP activity reprograms subsets of hepatocytes to different fates associated with deregulation of the HNF4A, CTNNB1, and E2F transcriptional programs that control hepatocyte quiescence and differentiation. Importantly, treatment with small interfering RNA-lipid nanoparticles (siRNA-LNPs) targeting YAP restores hepatocyte differentiation and causes pronounced tumor regression in a genetically engineered mouse HCC model. Furthermore, YAP targets are enriched in an aggressive human HCC subtype characterized by a proliferative signature and absence of CTNNB1 mutations. Thus, our work reveals Hippo signaling as a key regulator of the positional identity of hepatocytes, supports targeting of YAP using siRNA-LNPs as aparadigm of differentiation-based therapy, and identifies an HCC subtype that is potentially responsive to this approach

Original languageEnglish (US)
Pages (from-to)1692-1707
Number of pages16
JournalCell Reports
Volume10
Issue number10
DOIs
StatePublished - Mar 17 2015
Externally publishedYes

Fingerprint

Tumors
Hepatocytes
Hepatocellular Carcinoma
Neoplasms
Nanoparticles
Small Interfering RNA
Lipids
Deregulation
Liver
Tissue
Mutation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., ... Bardeesy, N. (2015). YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Reports, 10(10), 1692-1707. https://doi.org/10.1016/j.celrep.2015.02.027

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. / Fitamant, Julien; Kottakis, Filippos; Benhamouche, Samira; Tian, Helen S.; Chuvin, Nicolas; Parachoniak, Christine A.; Nagle, Julia M.; Perera, Rushika M.; Lapouge, Marjorie; Deshpande, Vikram; Zhu, Andrew X.; Lai, Albert; Min, Bosun; Hoshida, Yujin; Avruch, Joseph; Sia, Daniela; Campreciós, Genís; McClatchey, Andrea I.; Llovet, Josep M.; Morrissey, David; Raj, Lakshmi; Bardeesy, Nabeel.

In: Cell Reports, Vol. 10, No. 10, 17.03.2015, p. 1692-1707.

Research output: Contribution to journalArticle

Fitamant, J, Kottakis, F, Benhamouche, S, Tian, HS, Chuvin, N, Parachoniak, CA, Nagle, JM, Perera, RM, Lapouge, M, Deshpande, V, Zhu, AX, Lai, A, Min, B, Hoshida, Y, Avruch, J, Sia, D, Campreciós, G, McClatchey, AI, Llovet, JM, Morrissey, D, Raj, L & Bardeesy, N 2015, 'YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression', Cell Reports, vol. 10, no. 10, pp. 1692-1707. https://doi.org/10.1016/j.celrep.2015.02.027
Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA et al. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Reports. 2015 Mar 17;10(10):1692-1707. https://doi.org/10.1016/j.celrep.2015.02.027
Fitamant, Julien ; Kottakis, Filippos ; Benhamouche, Samira ; Tian, Helen S. ; Chuvin, Nicolas ; Parachoniak, Christine A. ; Nagle, Julia M. ; Perera, Rushika M. ; Lapouge, Marjorie ; Deshpande, Vikram ; Zhu, Andrew X. ; Lai, Albert ; Min, Bosun ; Hoshida, Yujin ; Avruch, Joseph ; Sia, Daniela ; Campreciós, Genís ; McClatchey, Andrea I. ; Llovet, Josep M. ; Morrissey, David ; Raj, Lakshmi ; Bardeesy, Nabeel. / YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. In: Cell Reports. 2015 ; Vol. 10, No. 10. pp. 1692-1707.
@article{71ea589f3e79425294f4b8ddbb389637,
title = "YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression",
abstract = "Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of YAP-mediated hepatocyte reprogramming and HCC pathogenesis. YAP functions as a rheostat in maintaining metabolic specialization, differentiation, and quiescence within the hepatocyte compartment. Increased or decreased YAP activity reprograms subsets of hepatocytes to different fates associated with deregulation of the HNF4A, CTNNB1, and E2F transcriptional programs that control hepatocyte quiescence and differentiation. Importantly, treatment with small interfering RNA-lipid nanoparticles (siRNA-LNPs) targeting YAP restores hepatocyte differentiation and causes pronounced tumor regression in a genetically engineered mouse HCC model. Furthermore, YAP targets are enriched in an aggressive human HCC subtype characterized by a proliferative signature and absence of CTNNB1 mutations. Thus, our work reveals Hippo signaling as a key regulator of the positional identity of hepatocytes, supports targeting of YAP using siRNA-LNPs as aparadigm of differentiation-based therapy, and identifies an HCC subtype that is potentially responsive to this approach",
author = "Julien Fitamant and Filippos Kottakis and Samira Benhamouche and Tian, {Helen S.} and Nicolas Chuvin and Parachoniak, {Christine A.} and Nagle, {Julia M.} and Perera, {Rushika M.} and Marjorie Lapouge and Vikram Deshpande and Zhu, {Andrew X.} and Albert Lai and Bosun Min and Yujin Hoshida and Joseph Avruch and Daniela Sia and Gen{\'i}s Campreci{\'o}s and McClatchey, {Andrea I.} and Llovet, {Josep M.} and David Morrissey and Lakshmi Raj and Nabeel Bardeesy",
year = "2015",
month = "3",
day = "17",
doi = "10.1016/j.celrep.2015.02.027",
language = "English (US)",
volume = "10",
pages = "1692--1707",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "10",

}

TY - JOUR

T1 - YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

AU - Fitamant, Julien

AU - Kottakis, Filippos

AU - Benhamouche, Samira

AU - Tian, Helen S.

AU - Chuvin, Nicolas

AU - Parachoniak, Christine A.

AU - Nagle, Julia M.

AU - Perera, Rushika M.

AU - Lapouge, Marjorie

AU - Deshpande, Vikram

AU - Zhu, Andrew X.

AU - Lai, Albert

AU - Min, Bosun

AU - Hoshida, Yujin

AU - Avruch, Joseph

AU - Sia, Daniela

AU - Campreciós, Genís

AU - McClatchey, Andrea I.

AU - Llovet, Josep M.

AU - Morrissey, David

AU - Raj, Lakshmi

AU - Bardeesy, Nabeel

PY - 2015/3/17

Y1 - 2015/3/17

N2 - Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of YAP-mediated hepatocyte reprogramming and HCC pathogenesis. YAP functions as a rheostat in maintaining metabolic specialization, differentiation, and quiescence within the hepatocyte compartment. Increased or decreased YAP activity reprograms subsets of hepatocytes to different fates associated with deregulation of the HNF4A, CTNNB1, and E2F transcriptional programs that control hepatocyte quiescence and differentiation. Importantly, treatment with small interfering RNA-lipid nanoparticles (siRNA-LNPs) targeting YAP restores hepatocyte differentiation and causes pronounced tumor regression in a genetically engineered mouse HCC model. Furthermore, YAP targets are enriched in an aggressive human HCC subtype characterized by a proliferative signature and absence of CTNNB1 mutations. Thus, our work reveals Hippo signaling as a key regulator of the positional identity of hepatocytes, supports targeting of YAP using siRNA-LNPs as aparadigm of differentiation-based therapy, and identifies an HCC subtype that is potentially responsive to this approach

AB - Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of YAP-mediated hepatocyte reprogramming and HCC pathogenesis. YAP functions as a rheostat in maintaining metabolic specialization, differentiation, and quiescence within the hepatocyte compartment. Increased or decreased YAP activity reprograms subsets of hepatocytes to different fates associated with deregulation of the HNF4A, CTNNB1, and E2F transcriptional programs that control hepatocyte quiescence and differentiation. Importantly, treatment with small interfering RNA-lipid nanoparticles (siRNA-LNPs) targeting YAP restores hepatocyte differentiation and causes pronounced tumor regression in a genetically engineered mouse HCC model. Furthermore, YAP targets are enriched in an aggressive human HCC subtype characterized by a proliferative signature and absence of CTNNB1 mutations. Thus, our work reveals Hippo signaling as a key regulator of the positional identity of hepatocytes, supports targeting of YAP using siRNA-LNPs as aparadigm of differentiation-based therapy, and identifies an HCC subtype that is potentially responsive to this approach

UR - http://www.scopus.com/inward/record.url?scp=84925103805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925103805&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2015.02.027

DO - 10.1016/j.celrep.2015.02.027

M3 - Article

C2 - 25772357

AN - SCOPUS:84925103805

VL - 10

SP - 1692

EP - 1707

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 10

ER -